Wegovy pricing in South Africa changed significantly in early 2026. Novo Nordisk announced two rounds of price reductions, citing market conditions and access concerns. The result is meaningfully more affordable medication, particularly during the early titration months.

Here is the current picture.

Current SA Pricing (Post March 2026 Reductions)

Starting dose
~R1,873
per month at 0.25 mg (down from R3,090)
Maintenance dose
~R3,746
per month at 2.4 mg (down 27%)

The middle doses (0.5 mg, 1 mg, 1.7 mg) sit between these two anchor points. A typical first four months of treatment, going through the titration on the lower doses, costs significantly less than maintenance at 2.4 mg.

A second price reduction was submitted by Novo Nordisk shortly after the first. Confirm current pricing with your chosen pharmacy.

Always confirm with your pharmacy Prices change with SEP updates and stock availability. Confirm the current cost at the pharmacy you plan to use before booking a consultation. Online Doctor SA's consultation fee is separate.

How Cost Scales With Dose

The titration means costs are lower in the early months. A typical pattern:

  • Month 1: 0.25 mg weekly. Lowest cost month.
  • Month 2: 0.5 mg weekly.
  • Month 3: 1 mg weekly.
  • Month 4: 1.7 mg weekly.
  • Month 5+: 2.4 mg weekly (or lower if responding well).

People who respond well at 1 mg or 1.7 mg and do not need to escalate to 2.4 mg keep ongoing costs lower than the maintenance dose figure.

Medical Aid Coverage

This is where SA pricing gets nuanced. Coverage varies considerably.

The PMB issue

Obesity is not on the Chronic Disease List (CDL) under the Medical Schemes Act's Prescribed Minimum Benefits framework. This means medical aids are not legally required to cover weight management medications, even when prescribed by a registered doctor.

This is a longstanding policy gap. Diabetes, hypertension, asthma, depression, and 22 other conditions are on the CDL. Obesity, despite being a recognised chronic medical condition globally, is not.

What schemes do cover

Some major SA schemes have specific provisions:

  • Discovery Health. Wegovy is covered from medical savings accounts (MSA) or available day-to-day benefits on most plans, subject to scheme rules.
  • Bonitas, Momentum, Fedhealth, GEMS. Variable cover, often through medical savings or specific benefits rather than chronic cover. Check directly.
  • Hospital plans. Generally no cover for outpatient weight management medications.

Practical step

Call your medical aid directly, quoting the medication name (Wegovy / semaglutide) and the intended use (chronic weight management). Ask whether it is on formulary, what the criteria are, and whether prior authorisation is needed.

Get An Assessment To Discuss Cost

The consulting doctor can help you understand what dose you are likely to settle on, which affects ongoing cost.

Start Consultation

How To Reduce Ongoing Cost

Confirm pharmacy pricing

Pricing varies between major retail pharmacies, independent pharmacies, and online dispensing pharmacies. Compare before settling on a regular supplier.

Stay at the lowest effective dose

Higher doses cost more. Many people respond well at 1 mg or 1.7 mg. There is no benefit to going to 2.4 mg if a lower dose produces the right outcome for you.

Medical savings optimisation

If your scheme covers from MSA, the medication uses your medical savings rather than your pocket. Maximising MSA usage on items that would otherwise come from pocket can effectively reduce the out of pocket impact.

Tax claim

Medical expenses, including out of pocket prescription medications, may be partially claimable depending on your tax situation. Keep your invoices.

What To Be Careful Of

Avoid unregulated 'cheap' alternatives There are websites, telehealth services, and even some clinics offering 'compounded semaglutide' outside the regulated pharmacy chain at much lower prices. These products are unregulated, often substandard, and sometimes falsified entirely. SAHPRA has issued specific warnings, and Novo Nordisk has pursued legal action against local compounders. According to industry reports, roughly one in two South Africans on weight loss treatment is using an unauthorised copy. Do not be part of that statistic. The Novo Nordisk product from a SAPC registered pharmacy is the safe regulated route. More on this.

Future Pricing

Three factors will likely shape future Wegovy pricing in SA:

  • Competition from Mounjaro has already pushed prices down once. Continued market pressure is likely to keep prices competitive.
  • Patent expiry for semaglutide is approaching in some markets (India saw generic semaglutide launch in early 2026). Patent expiry in SA is later but coming.
  • Medical aid policy may shift over time as the economic case for treating obesity becomes clearer. This is a slow but real trend.

Is It Worth The Cost

That is a personal calculation between the consulting doctor and the person. Considerations:

  • What conditions is the medication treating
  • What benefit is realistic given your specific situation
  • What is the cost of not treating (long term medical costs, quality of life, productivity)
  • What other treatment options are available at what cost and effectiveness

The medication is not a luxury purchase. It is treatment for serious chronic conditions. For people who meet the eligibility criteria and respond well, the health benefit is substantial.

Related Reading

Frequently Asked

Novo Nordisk announced two rounds of price reductions in early 2026, citing 'market conditions'. The starting dose dropped from R3,090 to R1,873 per month, with the maximum dose falling 27 percent.

Coverage is variable. Obesity is not on the Chronic Disease List under PMB regulations, so cover is not mandatory. Some schemes cover from medical savings accounts. Check directly.

Liraglutide (Saxenda) is an older GLP-1 medication at lower cost but daily injection and smaller average effect. Orlistat (Xenical) is much cheaper but produces modest weight loss.

Compounded semaglutide sold in SA outside the regulated pharmacy chain is cheaper but carries significant risks. SAHPRA has warned about substandard and falsified products. Read more.